ArticleDiscover oncology2026
PLXNA3 is overexpressed and promotes cell proliferation and migration in colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlexins (PLXNs) are cell surface receptors for class 3 semaphorins and play critical roles in immune regulation and tumorigenesis. Plexin A3 (PLXNA3) is involved primarily in nervous system development, but its function in colorectal cancer (CRC) remains poorly understood. Recent computational studies have identified PLXNA3 as a potential prognostic biomarker in CRC, yet experimental validation of its biological role is lacking.
methodsPLXNA3 expression and its prognostic significance were analyzed using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Immune infiltration correlations were assessed via TIMER2.0. Gene set enrichment analysis (GSEA) was performed to predict potential biological functions. For experimental validation, qRT‒PCR was used to assess PLXNA3 expression in CRC cell lines, and CCK-8, colony formation, and Transwell assays were conducted to evaluate the effects of PLXNA3 knockdown on cell proliferation and migration.
resultsPLXNA3 expression was significantly upregulated in CRC tissues and associated with poor overall survival in both the TCGA and GEO cohorts. High PLXNA3 expression correlated with advanced tumor stage and metastasis. PLXNA3 expression was positively correlated with the infiltration levels of CD4 + T cells, macrophages, neutrophils, and dendritic cells. Functional enrichment analysis suggested potential involvement in glucose metabolism and axonal guidance pathways. In vitro experiments confirmed that PLXNA3 is highly expressed in CRC cell lines and that its knockdown significantly suppresses cell proliferation and migration.
conclusionIn this study, experimental evidence is provided regarding the promotion of proliferation and migration of CRC by PLXNA3, complementing existing computational predictions. These findings support the role of PLXNA3 as a functionally validated oncogene in CRC and as a candidate for further therapeutic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.